Literature DB >> 9926143

Interstitial lung disease in systemic sclerosis: comparison of BALF lymphocyte phenotype and DLCO impairment.

J Domagała-Kulawik1, G Hoser, A Doboszyńska, J Kawiak, W Droszcz.   

Abstract

Patients with scleroderma (systemic sclerosis-SSc) frequently develop an interstitial lung disease. The role of lymphocytes in fibrosing alveolitis preceding lung fibrosis has been established. The purpose of this work was to evaluate cell profiles and lymphocyte phenotypes in the bronchoalveolar lavage (BAL) fluid and to correlate them with depression in lung function tests detected by depletion of diffusing capacity (DLCO). BAL was carried out in 25 untreated, non-smoking patients suffering from diffuse scleroderma and in 12 healthy non-smoking volunteers. For the analysis of lymphocyte sub-sets flow cytometry and monoclonal antibodies were used. The following cell sub-types were counted: T lymphocytes, B lymphocytes, helper lymphocytes, suppressor/cytotoxic lymphocytes, natural killer cells, cytotoxic T lymphocytes and activated T lymphocytes. The total cell count was higher in the group of patients with mild and moderate impairment in DLCO. The percentage of lymphocytes was greater in patients with DLCO lower than 65% of the predicted value since neutrophilia was found in patients with severe DLCO depletion, i.e. significant when compared with healthy subjects. The proportions of suppressor/cytotoxic lymphocytes and of activated T lymphocytes were higher in patients than in controls. The statistical analysis revealed significant differences between patients with moderate and mild changes in DLCO and the healthy volunteers. A decreased helper/suppressor ratio was noticed in these patients. We concluded that the BALF lymphocyte phenotype analysis may reflect the features of alveolitis in patients with SSc.

Entities:  

Mesh:

Year:  1998        PMID: 9926143     DOI: 10.1016/s0954-6111(98)90231-1

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  7 in total

Review 1.  Recognition and management of scleroderma in children.

Authors:  I Foeldvari; N Wulffraat
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

2.  Alterations of mononuclear inflammatory cells, CD4/CD8+ T cells, interleukin 1beta, and tumour necrosis factor alpha in the bronchoalveolar lavage fluid, peripheral blood, and skin of patients with systemic sclerosis.

Authors:  M R Hussein; H I Hassan; E R M Hofny; M Elkholy; N A Fatehy; A E A Abd Elmoniem; A M Ezz El-Din; O A Afifi; H G Rashed
Journal:  J Clin Pathol       Date:  2005-02       Impact factor: 3.411

3.  Improvement of lung function in patients with systemic sclerosis after 6 months cyclophosphamide pulse therapy.

Authors:  Predrag Ostojic; Nemanja Damjanov
Journal:  Clin Rheumatol       Date:  2006-01-27       Impact factor: 2.980

Review 4.  Interstitial lung disease in systemic sclerosis.

Authors:  Predrag Ostojic; Marco Matucci Cerinic; Richard Silver; Kristin Highland; Nemanja Damjanov
Journal:  Lung       Date:  2007 Jul-Aug       Impact factor: 2.584

5.  Induced sputum-retrieved matrix metalloproteinase 9 and tissue metalloproteinase inhibitor 1 in granulomatous diseases.

Authors:  E Fireman; Z Kraiem; O Sade; J Greif; Z Fireman
Journal:  Clin Exp Immunol       Date:  2002-11       Impact factor: 4.330

Review 6.  T and NK Cell Phenotypic Abnormalities in Systemic Sclerosis: a Cohort Study and a Comprehensive Literature Review.

Authors:  Isabel Almeida; Sara Vieira Silva; Ana Raquel Fonseca; Ivone Silva; Carlos Vasconcelos; Margarida Lima
Journal:  Clin Rev Allergy Immunol       Date:  2015-12       Impact factor: 8.667

7.  Natural Killer Cells Exhibit a Peculiar Phenotypic Profile in Systemic Sclerosis and Are Potent Inducers of Endothelial Microparticles Release.

Authors:  Audrey Benyamine; Jérémy Magalon; Florence Sabatier; Luc Lyonnet; Stéphane Robert; Chloé Dumoulin; Sophie Morange; Karin Mazodier; Gilles Kaplanski; Martine Reynaud-Gaubert; Pascal Rossi; Françoise Dignat-George; Brigitte Granel; Pascale Paul
Journal:  Front Immunol       Date:  2018-07-18       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.